Thr156
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr156  -  NHERF (human)

Site Information
ELRPRLCtMKKGPsG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3864004

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 , 2 ) , mass spectrometry ( 3 , 4 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
colorectal cancer ( 1 ) , colorectal carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
Akt1 (human) ( 2 ) , p90RSK (human) ( 1 )
Kinases, in vitro:
Akt1 (human) ( 2 ) , p90RSK (human) ( 1 )
Treatments:
Akt-I-1 ( 2 ) , serum ( 2 )

Downstream Regulation
Effects of modification on NHERF:
intracellular localization ( 1 ) , molecular association, regulation ( 2 )
Effects of modification on biological processes:
cell growth, induced ( 1 , 2 )
Induce interaction with:
SKP2 (human) ( 2 )

References 

1

Lim HC, Jou TS (2016) Ras-activated RSK1 phosphorylates EBP50 to regulate its nuclear localization and promote cell proliferation. Oncotarget 7, 10283-96
26862730   Curated Info

2

Song GJ, et al. (2015) Phosphorylation of Ezrin-Radixin-Moesin-binding Phosphoprotein 50 (EBP50) by Akt Promotes Stability and Mitogenic Function of S-phase Kinase-associated Protein-2 (Skp2). J Biol Chem 290, 2879-87
25492869   Curated Info

3

Possemato A (2008) CST Curation Set: 5688; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

4

Possemato A (2008) CST Curation Set: 4421; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info